GILEAD SCIENCES, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss (Deprecated 2018-01-31)
GILEAD SCIENCES, INC. (GILD) reported Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss (Deprecated 2018-01-31) of $27.00 thousand for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-25.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses · last filed 2014-02-25
- GILEAD SCIENCES, INC. available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate loss (deprecated 2018-01-31) for the quarter ending 2013-12-31 was -$93.00K.
- GILEAD SCIENCES, INC. available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate loss (deprecated 2018-01-31) for the quarter ending 2013-09-30 was -$40.00K.
- GILEAD SCIENCES, INC. available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate loss (deprecated 2018-01-31) for the quarter ending 2011-03-31 was $4.64M.
- GILEAD SCIENCES, INC. available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate loss (deprecated 2018-01-31) for fiscal 2013 was $27.00K.
- GILEAD SCIENCES, INC. available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate loss (deprecated 2018-01-31) for fiscal 2012 was $0.00.
- GILEAD SCIENCES, INC. available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate loss (deprecated 2018-01-31) for fiscal 2009 was $10.58M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss (Deprecated 2018-01-31) 3 month | Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss (Deprecated 2018-01-31) 6 month | Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss (Deprecated 2018-01-31) 9 month | Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2013-12-31 | -$93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$133.00K derived: sum of 2 quarters · filed 2014-02-25 | $27.00K 10-K · filed 2014-02-25 | |
| 2013-09-30 | -$40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-31 | $120.00K 10-Q · filed 2013-10-31 | ||
| 2013-06-30 | $160.00K 10-Q · filed 2013-08-01 | |||
| 2012-12-31 | $0.00 10-K · filed 2014-02-25 | |||
| 2011-03-31 | $4.64M 10-Q · filed 2011-05-09 | |||
| 2010-12-31 | $5.13M 10-Q · filed 2011-05-09 | |||
| 2009-12-31 | $10.58M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |